Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by Wino115on Jan 15, 2021 6:38pm
157 Views
Post# 32311804

RE:RE:RE:RE:RE:RE:RE:RE:Is it possible this deal falls through?

RE:RE:RE:RE:RE:RE:RE:RE:Is it possible this deal falls through?We know that would be the death knell for them ever going to market again and they appear to need to in about 3 years time unless things change a lot on the revenue side. You'd also lose those 3 bankers if you ask them to distribute to their clients and then you pull the rug out.  You have to have good news coming to interest new investors, not bad news.  This is just those retail guys who knew nothing about the deal and just listened to their brokers thinking all hot deals make them money. They'll bail as the momentum flip  trade didn't work. 


SPCEO1 wrote: Last trade now at $2.33 on about 16,000 shares. That is disconcerting for sure. Not sure how the deal could fall through as it is a bought deal and the mechanics of that have already been explained. But I suppose there could be more shares that need to be placed, although that also s eems highly unlikely as one of my contacts at one of the brokers involved said he got only a small percentage of what he was looking for his retail clients. So, it sounds like there were not enough shares rather than too many. And given how attractive the terms were, you would think that would have been the case.

The other alternative is there is bad news on the immediate horizon and that is why the deal was rushed. What might that be?

Perhaps they will have to announce that the EMA is not coming on board for the trial. But it is hard for me to see why that would be a big enough deal to rush this offering at a horrible price.

But it sure does smell like someone knows something and is trynig to get out before Monday. Hopefully, rather than pulling a rabbit out of their hat to make this odious deal look somewhat better, the company does not instead pull a bear out of its hat!

Bucknelly21 wrote: 2.35 after hours 




<< Previous
Bullboard Posts
Next >>